Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Waldencast plc - Class A Ordinary Share (NQ:WALD)

1.390 -0.050 (-3.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 47,510
Open 1.430
Bid (Size) 1.350 (200)
Ask (Size) 1.390 (100)
Prev. Close 1.440
Today's Range 1.390 - 1.450
52wk Range 0.7200 - 3.220
Shares Outstanding 9,342,874
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Waldencast Announces Completion of the Sale of Obagi Medical to Bridgepoint
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical Announces FDA Approval of Obagi® saypha® ChIQ™ Injectable Hyaluronic Acid Gel
Approval Further Expands Obagi Medical’s Injectable Portfolio and Strengthens Its Position as a Leading Dermatological Megabrand 
From Waldencast plc
Via GlobeNewswire

Performance

YTD
-18.7%
-18.7%
1 Month
-19.2%
-19.2%
3 Month
-16.8%
-16.8%
6 Month
-19.7%
-19.7%
1 Year
-15.2%
-15.2%

More News

Read More
Which stocks are experiencing notable movement on Monday? ↗
Via Chartmill
News headline image
Waldencast Announces Sale of Obagi Medical to Bridgepoint
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical Shares New Data on Recent Innovations at Music City Symposium for Cosmetic Advances & Laser Education (SCALE) Meeting
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi and Next Health Partner to Launch “The Skin Recharge Station” Pop-Up Experience
From Waldencast plc
Via GlobeNewswire
Unusual volume stocks are being observed in Thursday's session. ↗
Via Chartmill
News headline image
Obagi Medical Unveils New Mineral Sunscreen Designed to Protect Sensitive and Post-Procedure Skin*
From Waldencast plc
Via GlobeNewswire
Get insights into the top gainers and losers of Wednesday's pre-market session. ↗
Via Chartmill
News headline image
Waldencast announces conclusion of SEC investigation
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical Introduces NU-GEN™ Cellular Renewal Serum Designed to Visibly Rewind Skin’s Age and Restore Visible Youthfulness
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical and ProMD Announce Collaboration in the ALOHA Program to Advance Clinical Evidence with Obagi® saypha® MagIQ™
From Waldencast plc
Via GlobeNewswire
News headline image
Waldencast Reports Q4 2025 and FY 2025 Financial Results
From Waldencast plc
Via GlobeNewswire
News headline image
Waldencast plc Announces Fourth Quarter and Fiscal Year 2025 Earnings Date
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical and Schweiger Dermatology Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical and It’s a Secret Med Spa Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical and Aesthetic Record Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical and DermFx Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical and Moxie Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical Introduces New Lip Therapy Protocol Designed to Resurface, Replenish, and Protect
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical and VIO Med Spa Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical and Next Health Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
From Waldencast plc
Via GlobeNewswire
News headline image
UPDATE - Obagi Medical and Alpha Aesthetic Partners Announce Their Collaboration in the ALOHA Program to Drive Real-World Evidence with Obagi® saypha® MagIQ™
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical and Alpha Aesthetic Partners Announce Their Collaboration in the ALOHA Program to Drive Real-World Evidence with Obagi® saypha® MagIQ™
From Waldencast plc
Via GlobeNewswire
News headline image
CORRECTION – Obagi Medical and Platinum Dermatology Partners Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
From Waldencast plc
Via GlobeNewswire

Frequently Asked Questions

Is Waldencast plc - Class A Ordinary Share publicly traded?
Yes, Waldencast plc - Class A Ordinary Share is publicly traded.
What exchange does Waldencast plc - Class A Ordinary Share trade on?
Waldencast plc - Class A Ordinary Share trades on the Nasdaq Stock Market
What is the ticker symbol for Waldencast plc - Class A Ordinary Share?
The ticker symbol for Waldencast plc - Class A Ordinary Share is WALD on the Nasdaq Stock Market
What is the current price of Waldencast plc - Class A Ordinary Share?
The current price of Waldencast plc - Class A Ordinary Share is 1.390
When was Waldencast plc - Class A Ordinary Share last traded?
The last trade of Waldencast plc - Class A Ordinary Share was at 08/07/26 04:00 PM ET
What is the market capitalization of Waldencast plc - Class A Ordinary Share?
The market capitalization of Waldencast plc - Class A Ordinary Share is 12.99M
How many shares of Waldencast plc - Class A Ordinary Share are outstanding?
Waldencast plc - Class A Ordinary Share has 13M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.